Capsugel® Pharmaceutical capsule portfolio

An immediate-release capsule with an excellent dissolution profile, low moisture content, great machineability and visual quality.

Capsugel® Vcaps® Plus Capsules are available in different designs, allowing solid as well as liquid formulations.


For solid fills, Coni-Snap® design...

Demonstrated to protect acid-sensitive ingredients from degradation in the stomach.

Capsugel® DRcaps® HPMC Designed Release Capsules can help protect dietary supplement ingredients from stomach acidity without the cost and complexity of adding acid-resistant properties during manufacturing. DRcaps® ...

Vcaps® capsules are the first generation vegetarian capsules, meeting the needs of a wide variety of health-conscious consumers. With both KO and OU Kosher and Halal certification, and certified by the Vegetarian and Vegan Action Society, they are an appealing way to address the preferences of an important...

A tablet core encased in two high-gloss gelatin shells.

Differentiate your innovation from the nutraceutical market with Capsugel® Press-Fit® and XPress-Fit® Gelcaps. They offer a high-gloss gelatin cover for your health ingredients allowing a volume reduction from 26 to 40% compared to a regular Ca...

The Capsugel® capsule portfolio provides a wide variety of high-quality products and technologies to help you create a customized solution to bring new innovations to market.Our broad capsule portfolio delivers highly functional and appealing products to extend your market rea...

Empower active lifestyles with UC-II® undenatured type II collagen

UC-II® undenatured type II collagen is the most researched undenatured type II collagen brand* that is clinically studied to maintain or support joint comfort and mobility with one small daily dose of 40 mg a day.

With mor...

Capsugel® Enprotect® is a ready-to-use enteric capsule with acid resistance up to pH 6.0, eliminating the need for post-filling coating.

Building on the Capsugel® legacy of developing and launching new and innovative capsules, we have developed a first-of-its-kind manufacturing process. 
qq...

Your Partner In Oral And Inhaled Dosage Formulation And Delivery

At Lonza, we’re driven by our purpose to enable a healthier world. It’s the “why” behind everything we do and it’s the driving force behind Innovaform™ Accelerator: our center of excellence in the development of new drug delivery syste...

Plantcaps® capsules, a vegetarian capsule made from pullulan – naturally fermented from tapioca – for a more extensive and distinctive appeal to the booming and discerning healthy lifestyle market worldwide.
Plantcaps® capsules are the premium capsules designed for the needs of the growing and very di...

A simple way for pre-clinical oral administration of pharmaceutical actives and formulations to rodents

PCcaps® Capsules facilitate the administration of early-phase formulations, whether powder or granules, paste, or non-aqueous liquids. 

With PCcaps® Capsules, you can avoid the use of ...

DBcaps® Over-Encapsulation Capsules are developed with a tamper-evident and easy-to-swallow design to specifically address the clinical trial challenges without bias in double-blind tests.
Available as gelatin or HPMC capsules.

Capsugel® Zephyr® Inhalation Capsules offer consistent powder release, a customized approach to optimize performance of the end product. Expertly engineered to minimize powder retention, our capsules ensure the maximum amount of medication is delivered directly to the lungs. We have compatibility studies a...

Explore Lonza new innovation center, dedicated to accelerating capsule development for oral and pulmonary drug delivery. Join us to discover how we foster collaboration with customers and co-innovation in a cutting-edge environment where science meets ingenuity. Learn how our expert team tackles complex formulation challenges, navigates global regulatory requirements, and supports your journey from concept to market. Experience how Lonza can partner with you to redefine the future of pharmaceutical excellence.

In this webinar, formulation scientists and pharmaceutical development specialists will learn how Lonza’s Capsule Applications Services lab can address drug solubility limitations, develop innovative capsules to tailor drug delivery, and optimize encapsulation processes.


Click here to register

The next generation enteric capsule enables pharmaceutical companies to develop a targeted delivery solution while simplifying their manufacturing processes.

The solution offers: An acid-protective dosage form with enteric drug release through a patient centric delivery solution; A simple encapsulation process that allows for fast and stable preparation.

This solution is supported by scientific studies, both in-vitro and in-vivo, showing that enteric protection and targeted delivery to the distal intestine are achieved in comparison to marketed references.

Backed up also by performance studies, this capsule showcases excellent machineability and mechanical properties, in line with standard immediate release HPMC capsules. It is available commercially in large quantities.

Join Dr. Vincent Jannin to learn more on the newly launched enteric solution.

This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. Forefront Key Formulation Variables & Approaches Formulation Development of Complex Oral Dosage Forms Discuss innovations & emergence of advanced technologies (e.g., 3D Printing) Main Driver and Areas of Growth for Oral-Dose Outsourcing Patient-Centric Innovation

This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. The session discusses: Colour in Health products: insights and perspectives The Colour Lab Services and how it can help you define your next coloured product Titanium dioxide discussion and Lonza CHI solutions

The Capsugel®️ capsule portfolio provides a wide variety of high-quality products and technologies to help you create a customized solution to bring new innovations to market.

As the pharmaceutical industry advances toward more targeted, patient-centric therapies, the need for delivery technologies that bypass the stomach has become critical. Lonza’s Capsugel® Enprotect® capsule represents a breakthrough in enteric technology—offering a bi-layered, ready-to-use solution that protects acid-sensitive APIs without the need for subsequent coating or additional unit operations. This innovation accelerates development timelines and enhances formulation flexibility across a range of modalities, including small molecules, peptides, and live biotherapeutic products. Coupled with Lonza’s Innovaform® Accelerator, Enprotect® capsules can be fully customized to meet molecule and brand requirements, ensuring compatibility and optimized release profiles. This session will explore how Lonza’s products and services enable accelerated, tailored development of oral solid dosage forms, including a full-service pathway from concept-to-patient through Lonza’s cGMP clinical and commercial manufacturing capabilities. Discover how Lonza is redefining what’s possible in oral drug delivery—offering not just a capsule, but a complete solution.

As the pharmaceutical industry confronts the dual challenge of delivering health solutions while reducing its environmental footprint, the journey to net zero has become both a strategic imperative and a moral responsibility. The challenges that pharma manufacturers, and in particular excipient manufacturers, face are multifaceted: driving sustainable transformation in manufacturing processes, balancing economic and environmental yields, and building roadmaps that bridge ambition with action—while also satisfying quality, regulatory, compliance, and customer needs. In this plenary session, we will explore how Lonza CHI's capsule manufacturing has turned sustainable manufacturing from a cost driver into a customer value add, translating climate ambition into operational reality—through smart investments, structured roadmaps, and a deeply embedded culture of sustainability. We will draw from real-world examples of CHI’s capsule manufacturing transformation and provide a structured approach to building credible roadmaps that drive measurable results and help eco-design future formulations.

The pharmaceutical and nutraceutical industries are under growing pressure to reduce their environmental impact, along the value chain: from downstream to own manufacturing, to upstream supply chain. Manufacturing of excipients and capsules can become an important step in the journey for emissions reduction. At Lonza Capsules & Health Ingredients, we’ve made significant strides in decarbonizing our operations—through automation, energy efficiency, and sustainable design—while maintaining high standards for product quality and regulatory compliance.

In this webinar, you will learn how Lonza is tackling Scope 1, 2, and 3 emissions in capsule manufacturing through waste heat recovery, renewable energy integration, and data-driven sustainability strategies. Our experts will walk you through key innovations, measurable outcomes, and how these efforts are contributing to product-level carbon footprint reductions.